Editorial
doi: 10.7326/M18-3632.
Epub 2019 Jan 1.
A Pound of Prevention? Assessing the Value of New Cholesterol-Lowering Drugs
Affiliations
- PMID: 30597487
- DOI: 10.7326/M18-3632
Item in Clipboard
Editorial
A Pound of Prevention? Assessing the Value of New Cholesterol-Lowering Drugs
Ann Intern Med.
.
No abstract available
Comment on
-
Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.Ann Intern Med. 2019 Feb 19;170(4):221-229. doi: 10.7326/M18-1776. Epub 2019 Jan 1. Ann Intern Med. 2019. PMID: 30597485
Similar articles
-
A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom.Pharmacoeconomics. 2003;21 Suppl 1:25-32. doi: 10.2165/00019053-200321001-00003. Pharmacoeconomics. 2003. PMID: 12648032 Clinical Trial.
-
Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.Pharmacol Ther. 2016 Aug;164:183-94. doi: 10.1016/j.pharmthera.2016.04.011. Epub 2016 Apr 29. Pharmacol Ther. 2016. PMID: 27133571 Review.
-
[When cholesterol lowering drugs should not be too expensive. Statins are especially effective in secondary prevention].MMW Fortschr Med. 2000 Jul 27;142(30):33-4. MMW Fortschr Med. 2000. PMID: 10955017 German. No abstract available.
-
Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.High Blood Press Cardiovasc Prev. 2016 Sep;23(3):217-30. doi: 10.1007/s40292-016-0155-2. Epub 2016 Aug 27. High Blood Press Cardiovasc Prev. 2016. PMID: 27567901 Free PMC article. Review.
-
Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.Vasc Health Risk Manag. 2017 Jul 6;13:247-253. doi: 10.2147/VHRM.S133690. eCollection 2017. Vasc Health Risk Manag. 2017. PMID: 28740397 Free PMC article.
Cited by
-
A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates.NPJ Vaccines. 2023 Sep 28;8(1):142. doi: 10.1038/s41541-023-00743-6. NPJ Vaccines. 2023. PMID: 37770440 Free PMC article.
-
A Virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in Non-Human Primates.bioRxiv [Preprint]. 2023 May 15:2023.05.15.540560. doi: 10.1101/2023.05.15.540560. bioRxiv. 2023. Update in: NPJ Vaccines. 2023 Sep 28;8(1):142. doi: 10.1038/s41541-023-00743-6. PMID: 37292981 Free PMC article. Updated. Preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
